Xiromed LLC, a New Jersey-based generic pharmaceutical company, has launched 6 new generic pharmaceutical product in the US: Jaimiess™ (Levonorgestrel and Ethinyl Estradiol Tablets, USP and Ethinyl Estradiol Tablets, USP), generic to Seasonique®; LoJaimiess® (Levonorgestrel and Ethinyl Estradiol Tablets, USP and Ethinyl Estradiol Tablets, USP), generic to LoSeasonique®; Volnea® (Desogestrel and Ethinyl Estradiol Tablets, USP and Ethinyl Estradiol Tablets, USP), generic to Mircette®; Deferasirox Tablets, 90 mg and 360 mg strengths, generic to Jadenu®, Norethindrone Acetate and Ethinyl Estradiol Chewable Tablets and Ferrous Fumarate Tablets, generic to Minastrin® 24 FE; and Acyclovir Ointment USP, 5%, generic to Zovirax®. The launch of these six products enhances our robust portfolio of generic pharmaceutical products, furthering our commitment to providing high quality generics to patients in the US.
Xiromed LLC is the US generic division of Insud Pharma, S.L., a global pharmaceutical company headquartered in Madrid, Spain. Xiromed is focused on developing and commercializing high quality generic pharmaceutical products for the US market. In addition to its commercial portfolio of generics available in the US, Xiromed has a robust development portfolio of generic pharmaceutical products in various stages of development, including injectable, inhalation and complex generic products. Learn more at http://www.xiromed.com/usa/